Kevin Gillis
Direttore Finanziario/CFO presso Third Rock Ventures LLC
Provenienza dei contatti di primo grado di Kevin Gillis
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.
119
| Private Company | Investment Managers | 119 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kevin Gillis tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Director of Finance/CFO Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree Graduate Degree Undergraduate Degree Graduate Degree | |
| Stanford University | College/University | Graduate Degree Graduate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director of Finance/CFO Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Undergraduate Degree Graduate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| CONSTELLATION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer President Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Chairman Founder Founder Corporate Officer/Principal Founder Chief Tech/Sci/R&D Officer | |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Biotechnology | Chairman Private Equity Investor Director/Board Member Founder Director/Board Member Consultant / Advisor | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Chairman Chief Tech/Sci/R&D Officer Corporate Officer/Principal Director/Board Member Chief Executive Officer Founder | |
| NEON THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer Founder | |
| RELAY THERAPEUTICS, INC. | Biotechnology | Founder Founder Director/Board Member Corporate Officer/Principal Director/Board Member Founder | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member Director/Board Member Consultant / Advisor | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Boston College | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin Undergraduate Degree Doctorate Degree | |
| FOUNDATION MEDICINE INC | Medical/Nursing Services | Director/Board Member Director/Board Member Chief Executive Officer President Human Resources Officer | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Septerna, Inc.
 Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Pharmaceuticals: Major | Chairman Founder Chief Operating Officer Director/Board Member | |
| SAGE THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chairman Chief Operating Officer Corporate Officer/Principal | |
| GLOBAL BLOOD THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Founder Director/Board Member Founder | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Tango Therapeutics Sub, Inc.
 Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| PLIANT THERAPEUTICS, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Director/Board Member Undergraduate Degree Graduate Degree Doctorate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Pennsylvania | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| TANGO THERAPEUTICS, INC. | Biotechnology | Chairman Director/Board Member Chief Executive Officer Private Equity Investor | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Chief Tech/Sci/R&D Officer Private Equity Investor | |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
Celsius Therapeutics, Inc.
 Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| NURIX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Founder Director/Board Member Director/Board Member | |
| EDITAS MEDICINE, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal Private Equity Investor | |
Casma Therapeutics, Inc.
 Casma Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Casma Therapeutics, Inc. operates biotechnology company harnessing natural cellular process of autophagy to design new medicines. The company was founded by Cary Pfeffer and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Founder Founder Founder | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
| Georgetown University | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| DECIBEL THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Stati Uniti | 49 |
| Regno Unito | 2 |
| Svizzera | 2 |
Settori
| Health Technology | 33 |
| Consumer Services | 13 |
| Commercial Services | 5 |
| Finance | 2 |
| Health Services | 2 |
Posizioni
| Director/Board Member | 416 |
| Corporate Officer/Principal | 247 |
| Independent Dir/Board Member | 122 |
| Private Equity Investor | 102 |
| Chairman | 98 |
Contatti più connessi
| Insiders | |
|---|---|
| Steven Paul | 39 |
| Perry Karsen | 38 |
| Neil Exter | 33 |
| Daniel Lynch | 32 |
| Charles Homcy | 28 |
| Stephen Sherwin | 26 |
| Mark Levin | 26 |
| Mary Lynne Hedley | 25 |
| James Geraghty | 25 |
| Alexis Borisy | 25 |
| Robert Tepper | 24 |
| Abbie Celniker | 23 |
| Cameron Wheeler | 20 |
| R. Alan B. Ezekowitz | 20 |
| Robert Kamen | 19 |
- Borsa valori
- Insiders
- Kevin Gillis
- Connessioni Società
